Technical / White Paper

New study of Angel® yeast beta-glucan shows efficacy in improving Alzheimer's disease by regulating gut microbiota and metabolites

Format: PDF file | Document type: Technical / White Paper

New study of Angel® yeast beta-glucan shows efficacy in improving Alzheimer's disease by regulating gut microbiota and metabolites

A recent study published by Angel Yeast Co., Ltd. on International Journal of Biological Macromolecules attracted much attention. Researchers found that yeast beta-glucan was related to a series of gut-brain axis events and can improve neuroinflammation and brain insulin resistance, which means that yeast beta-glucan may prevent Alzheimer's disease. This study broadened the potential applications of yeast beta-glucan as a novel dietary supplement to prevent early-stage pathologies associated with AD.

Yeast beta-glucan is a polysaccharide derived from Saccharomyces cerevisiae​, with featured molecular structure of a linear beta-(1, 3)-glucan backbone with beta-(1, 6)-linked side chains. It shows stronger biological activities than other sources of beta-glucans especially in immunity enhancing. “Nowadays, AD has become a global healthy problem, this study unveiled the relationship between yeast beta-glucan and AD, presenting a potential way to improve AD.” Said Poshy Zhang, R&D director of Angel Yeast Human Health Division.

Latest content from Angel Yeast Co., Ltd.

Angel Yeast beta-glucan won the Golden Patent Award

Content provided by Angel Yeast Co., Ltd.

Angel Yeast beta-glucan won the Golden Patent Award

In December 2018, the patent Method for preparing glucan and mannan, glucan preparation and mannan preparation produced thereby and use thereof (ZL200810105516.7) won the Golden Patent Award in China.

Supplier info centre